BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 1,200 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down $1.38 during trading hours on Monday, hitting $83.62. The stock had a trading volume of 736,595 shares, compared to its average volume of 1,225,378. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a twelve month low of $79.50 and a twelve month high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the business earned $0.02 earnings per share. The business’s revenue was up 19.4% on a year-over-year basis. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.65 EPS for the current fiscal year.

Several large investors have recently modified their holdings of BMRN. Dimensional Fund Advisors LP lifted its position in shares of BioMarin Pharmaceutical by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 188,147 shares of the biotechnology company’s stock valued at $16,517,000 after acquiring an additional 7,501 shares in the last quarter. US Bancorp DE lifted its position in shares of BioMarin Pharmaceutical by 2.5% in the second quarter. US Bancorp DE now owns 8,034 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 198 shares in the last quarter. NGAM Advisors L.P. lifted its position in shares of BioMarin Pharmaceutical by 0.4% in the second quarter. NGAM Advisors L.P. now owns 15,245 shares of the biotechnology company’s stock valued at $1,385,000 after acquiring an additional 55 shares in the last quarter. Great West Life Assurance Co. Can lifted its position in shares of BioMarin Pharmaceutical by 2.4% in the second quarter. Great West Life Assurance Co. Can now owns 144,339 shares of the biotechnology company’s stock valued at $13,095,000 after acquiring an additional 3,432 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of BioMarin Pharmaceutical by 5.7% in the second quarter. CIBC Asset Management Inc now owns 12,518 shares of the biotechnology company’s stock valued at $1,137,000 after acquiring an additional 680 shares in the last quarter. Institutional investors and hedge funds own 99.26% of the company’s stock.

A number of research analysts recently weighed in on BMRN shares. Zacks Investment Research lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Piper Jaffray Companies started coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They set an “overweight” rating and a $113.00 price objective on the stock. Citigroup started coverage on BioMarin Pharmaceutical in a report on Thursday, August 31st. They set a “buy” rating and a $98.00 price objective on the stock. Royal Bank Of Canada started coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 target price on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and set a $117.00 target price (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the stock. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and an average price target of $111.59.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/04/insider-selling-biomarin-pharmaceutical-inc-bmrn-evp-sells-1200-shares-of-stock.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.